Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug aims to shrink hard-to-treat tumors in 30 patients

NCT ID NCT06365840

First seen Apr 18, 2026 · Last updated May 24, 2026 · Updated 4 times

Summary

This study tests an experimental drug called IMC-001 in 30 adults with advanced solid tumors that have many genetic mutations (TMB-H). The goal is to see if the drug can shrink tumors and control the disease. Participants must have a tumor sample available for testing and at least one measurable tumor.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TMB-H are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Cancer Center

    RECRUITING

    Goyang, South Korea

    Contact

  • Samsung Medical Center

    RECRUITING

    Seoul, South Korea

    Contact

  • Seoul National University Bundang Hospital

    RECRUITING

    Seongnam, South Korea

    Contact

  • Severance Hospital

    RECRUITING

    Seoul, South Korea

    Contact

Conditions

Explore the condition pages connected to this study.